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B
iomedicalnanotechnologyhasunder-
gone considerable progress over the
past ﬁve decades, from an initial de-
monstration of liposomes
1,2 to that of a
logic-gated nanorobot.
3 Much of this devel-
opment has focused on improving the
detection and treatment of cancer by in-
creasing the bioavailability and targeting
speciﬁcity of anticancer agents.
4 11 The
rapidly growing ﬁeld of structural DNA
nanotechnology
12 16 could advance these
aims by expanding the range of available
nanoparticle geometries and improving
the precision of ligand functionalization,
two key design parameters. Even more
exciting is DNA nanotechnology's potential
for engineering of highly sophisticated
nanoscale devices. Recent studies include
the nanorobot,
3 programmable immuno-
adjuvants,
17,18 a synthetic membrane chan-
nel,
19 and a molecular cascade capable of
autonomously processing multiple inputs
to determine cell phenotype.
20 Translation
ofsuchdevicesintobiomedicalapplications
requires molecular engineers to ﬁrst ad-
dress the susceptibility of DNA nanostruc-
tures to nuclease degradation,
21 as well as
their ability to activate an inﬂammatory
immune response.
17,22 Inspired by the sta-
bility provided to enveloped viruses via
theirlipidmembranes,wedevelopedenvel-
oped DNA nanostructures that address the
above challenges (Figure 1a).
RESULTS AND DISCUSSION
To mimic the geometry of a viral protein
capsid shell, we designed a wireframe DNA
nano-octahedron (DNO) with an estimated
diameter of ∼50 nm (Supporting Informa-
tion Figure 1).
23 The octahedron struts are
each composed of a bundle of six ∼28 nm
long double helices
14,24 engineered with a
∼90 curvature (see Supporting Informa-
tion Note 1).
15 DNOs were self-assembled
in a one-pot reaction by combining phage-
derived scaﬀold DNA (p7308)
25 with 144
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ABSTRACT DNA nanotechnology enables engineering of
molecular-scale devices with exquisite control over geometry and
site-speciﬁc functionalization. This capability promises compelling
advantages in advancing nanomedicine; nevertheless, instability in
biological environments and innate immune activation remain as
obstacles for in vivo application. Natural particle systems (i.e.,
viruses) have evolved mechanisms to maintain structural integrity
andavoidimmunerecognitionduringinfection,includingencapsula-
tionoftheirgenomeandproteincapsidshellinalipidenvelope.Here
we introduce virus-inspired enveloped DNA nanostructures as a design strategy for biomedical applications. Achieving a high yield of tightly wrapped
unilamellar nanostructures, mimicking the morphology of enveloped virus particles, required precise control over the density of attached lipid conjugates
and was achieved at 1 per ∼180 nm
2. Envelopment of DNA nanostructures in PEGylated lipid bilayers conferred protection against nuclease digestion.
Immuneactivationwasdecreased2ordersofmagnitudebelowcontrols,andpharmacokineticbioavailabilityimprovedbyafactorof17.Byestablishinga
designstrategysuitableforbiomedicalapplications,wehaveprovidedaplatformfortheengineeringofsophisticated,translation-readyDNAnanodevices.
KEYWORDS: DNA . nanotechnology . lipid bilayer . in vivo . nanostructure . imaging . immune . pharmacokinetics .
biodistribution . PEG
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oligonucleotide staple strands (see Supporting Infor-
mation Table 1) in a 15 h thermal annealing ramp.
Correctly folded structures were isolated by glycerol 
gradient centrifugation
26 and veriﬁed by negative-
stain transmission electron microscopy (TEM) (Figure 1b
and Supporting Information Figure 2).
Functional molecular features coupled to oligonu-
cleotides can be assembled onto DNA nanostructures
with high precision through hybridization to single-
stranded DNA “handles” designed into the nanostruc-
ture. We designed an “inner” set of 12 identical
handles (protruding from the inside face of the DNO
struts) for attachment of ﬂuorophore-conjugated
oligonucleotides, providing optical contrast agent
functionality. We designed a second “outer” set of 48
handles (protruding from the outside face) for attach-
ment of lipid-conjugated oligonucleotides
27 with the
lipid positioned ∼5 nm (2 nm 6-thymidine spacer þ
2.5 nm double helix width þ 0.5 nm linker for lipid)
from the nanostructure frame to drive tight wrapping
of the membrane around the structure.
Our encapsulation strategy involves directing lipid
bilayer assembly around DNO, recruited by individ-
ual lipid-conjugated oligonucleotides preassembled
onto outer handles. Thelipidbilayersarereconstituted
out of a solution of mixed lipid and surfactant
Figure 1. Schematic of the encapsulation strategy and negative-stain TEM. (a) Lipid DNA conjugates are annealed to outer
handles of non-encapsulated DNA nano-octahedron (N-DNO) in a surfactant solution that forms micelles around the
conjugates. Liposomes are added, resulting in mixed surfactant lipid micelles. Dialysis selectively removes the surfactant
and results in a fused lipid bilayer around the DNO. (b) TEM images of puriﬁed N-DNO, (c) E-DNO, showing a tightly wrapped
unilamellar membrane around the nanostructures, and (d) phi12 bacteriophage, showing comparable ultrastructure and
dimensions to E-DNO (scale bar = 50 nm).
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(N-octyl-β-D-glucopyranoside) through a dialysis step
thatselectivelyremovesthesurfactant
28toachievethe
desired encapsulated DNO (E-DNO) (Figure 1c). We
refer to DNO that has not been treated with lipids as
non-encapsulatedDNO(N-DNO).Unlessotherwisestated,
our membrane formulation includes 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) (94.2% molar contri-
bution), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethyleneglycol)-2000] (PEG-DOPE) (5%),
and ﬂuorescent rhodamine-1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (Rh-DOPE) (0.8%).
We measured internalized DNO diameters of 53 nm
versus outer membrane diameters of 76 ( 4n m
from TEM images of E-DNO (Supporting Information
Figure3).Ourmembraneformulationhasanestimated
thickness of ∼4 nm lipid bilayer plus ∼5 nm of PEG on
each leaﬂet; therefore, the observed diﬀerential of
∼12nmpervesiclesideisconsistentwithaunilamellar
envelope. As anticipated based on our design inspira-
tion, the ultrastructure and dimensions of E-DNO are
similar to enveloped virus particles (e.g., phi12 bacte-
riophage, Figure 1d)
29 with our nanostructure taking
the place of the protein capsid shell, wrapped tightly
by a single lipid bilayer.
To optimize our bilayer reconstitution strategy, we
synthesized additional variants of DNO having 0, 12, or
24 outer handles. After subjecting these to the lipid
treatment described above, we examined the extent
of association between nanostructures and vesicles
using a membrane-impermeable DNA dye (PicoGreen).
Fluorescence-based quantiﬁcation of DNO before and
after membrane destabilization with surfactant re-
vealed a direct correlation between outer handle
number and the percent of nanostructures inaccessi-
ble to the dye (Figure 2a). We observed 20.2 ( 3.5%
((SEM) of the 0 handle variant was membrane-
enclosed, suggesting there is a nonspeciﬁc interaction
between the DNA and lipids. This could be tuned by
addition of negatively charged lipid (15% 1,2-dioleoyl-
sn-glycero-3-phospho-L-serine) to the membrane for-
mulation, which decreased the nonspeciﬁc interaction
to 5.1 ( 2.7% (Supporting Information Figure 4). The
variant with 12 outer handles at an average density of ∼1
handleper710nm
2ofnanostructuresurface(surfacearea
isdeﬁned as that ofa sphereenclosing the DNO) showed
43.9(3.1%membrane-enclosed. Acomparable48.3(
3.5% was measured with 24 handles (1 handle per
∼350 nm
2). The association between DNO and mem-
branes was strongest with our design maximum of 48
outer handles (1 handle per 180 nm
2/handle), which
showed 68.1 ( 7.3% enclosed within membranes.
We thentested protection from nuclease activity via
DNase I digestion (Figure 2a). Following lipid treat-
ment, 1.5 μg of each variant was incubated with 20
units of enzyme for 24 h at 37 C, and total remaining
DNA was quantiﬁed by PicoGreen ﬂuorescence and
compared to non-nuclease-treated controls. The 0
outer handle sample showed little protection with
30.4 ( 2.3% DNA remaining, whereas 84.6 ( 7.2%
remained in the 48 outer handle sample, clearly
Figure 2. Bulk encapsulation yield and in vitro immune activation. (a) Encapsulation yield of outer handle DNO variants was
estimatedbyPicoGreendyemembrane exclusion(red),andprotectionfromnucleasewasassayedwithDNaseI(blue). ELISA
assay measurements of (b) IL-6 and (c) IL-12 cytokine production by splenocytes after incubation with N-DNO, E-DNO, and
50 nm vesicles for 16 h, as well as nonactivated controls. (d) Flow cytometry measurement of splenocyte mean ﬂuorescence
after incubation with Cy5-labeled N-DNO, E-DNO, and negative control. (e) Flow cytometry forward- (cell size) and side-
scattering (granularity) properties of splenocytes was used to deﬁne two populations. Small, low granularity cells (1) were
analyzed separately from large, high granularity cells (2). (f) Histogram of population (2) ﬂuorescence after incubation with
Cy5-labeledN-DNO(purple),E-DNO(blue),andnegativecontrols(red).(*a,b:p<0.05,ANOVAþDunnet'stestvscontrol,error
bars indicate SEM).
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showingthattheenvelopeprovidesprotectionagainst
nuclease digestion.
Negative-stainTEMrevealedafarmoredramaticim-
pact of handle number on ultrastructure (Supporting
Information Figure 5). Whereas most 0 handle DNOs
were not associated with vesicles, those with 12 or 24
outer handles had much of their surface covered by
vesicles formed external to the nanostructure frame.
Imaging of 48 handle DNO revealed nanostructures
withinapparentlycompleteandtightlyassociatedlipid
bilayers, as shown in Figure 1c. The number and
density of attached lipid-conjugated oligonucleotides
is therefore a key design parameter for DNO encapsu-
lation. Successful encapsulation was also dependent
on the liposome formulation. Removal of PEG-DOPE
resulted in much larger reconstituted vesicles and no
tightly wrapped nanostructures, suggesting that PEG
plays an important role in controlling the extent of
micellefusion.Weobservedthatcholesterol(∼5%)can
be used in place of PEG-DOPE to similarly control
micellefusionandtoproduceE-DNO(datanotshown).
Inclusion of both PEG (5%) and cholesterol (15%)
causedstabilization ofreconstitutedvesiclesatsmaller
diameters, suggesting an inhibition of fusion and
trapping of a putative intermediate of the encapsula-
tion process (Supporting Information Figure 6).
We next used density equilibrium centrifugation in an
iodixanol gradient to separate 48 outer handle E-DNO
from excess lipid vesicles, resulting in a highly enriched
population (Supporting Information Figure 7). The ﬁnal
recovery yield of E-DNO relative to starting number of
DNO used in encapsulation and the fraction of fully
encapsulated nanostructures were determined by Pico-
Green quantiﬁcation and membrane exclusion to be ∼20
and 90%, respectively. This yield allowed us to prepare
quantitiesofE-DNOsuitableforinvitroandinvivostudies.
A signiﬁcant innate inﬂammatory response would
be a serious impediment to many biomedical applica-
tions of DNA nanotechnology. As a gauge of this, we
incubatedCy-5-labeledN-andE-DNO,aswellasempty
50nmvesicles,withimmunecellsisolatedfrommouse
spleens. Similar to previously reported results,
17,18
N-DNO activated a potent inﬂammatory cytokine re-
sponsecomparabletothatproducedfromexposureto
bacterial or viral nucleic acids. Interleuken-6 (IL-6) and
IL-12 were produced at 136 ( 10- and 99 ( 5-fold
above nonactivated cells (Figure 2b,c). In contrast,
E-DNO and 50 nm vesicles induced 2.1 ( 0.3- and
0.9(0.3-foldincreases,respectively,inIL-6production
versus controls. Similarly, IL-12 was undetectable after
incubation with E-DNO and vesicles. Flow cytometry
showed that mean ﬂuorescence of splenocytes incu-
bated with N-DNO was 111 ( 8-fold higher than with
E-DNO, which was equivalent to negative control cells
(Figure 2d). N-DNO uptake was concentrated in a
subpopulation of large, granular cells (Figure 2e,f) in
which89.0(3.2%displayedverybrightCy5signal.This
same subpopulation showed low mean ﬂuorescence
and fewpositivecells (8.0 ( 2.3%) afterincubation with
E-DNO, a result that was conﬁrmed by confocal micro-
scopy (Supporting Information Figure 8). This spleno-
cyte assay shows that nanostructure activation of, and
uptake by, immune cells can be almost fully attenuated
by encapsulation in a PEGylated lipid membrane.
Encouraged by this, we next aimed to characterize
the in vivo pharmacokinetics of E-DNO. AlexaFluor750-
labeled oligonucleotides, N-DNO, and E-DNO were in-
travenously injected into anaesthetized mice to allow
tracking via whole animal optical imaging for 120 min
postinjection. Elimination half-life of the oligonucleo-
tide control was estimated to be 38.0 ( 0.8 min, with
signal rapidly accumulating in the bladder immedi-
ately after injection (Figure 3a,b). The half-life (49.5 (
1.0 min) and clearance pattern of N-DNO were equiva-
lent to the that of the oligonucleotide. Because nano-
particles larger than 6 nm are size-excluded from renal
clearance,
30 these data indicate that the structural
integrityofN-DNObecomescompromisedimmediately
after injection. In contrast, E-DNO displayed an esti-
mated half-life of370 ( 38 min (Figure 3c), comparable
to similarly formulated PEGylated liposomes,
4 with little
bladder accumulation.IncomparisontoN-DNO,encap-
sulation increased the elimination half-life and relative
bioavailability by factors of 9 and 17, respectively.
The stability of DNA nanostructures and devices has
previouslybeenprobedduringexposuretolysatefrom
sodium dodecyl sulfate-treated mammalian cells,
31
andafterdirectinjectionintoCaenorhabditiselegans,
32
with little degradation observed. Comparison to our
ﬁndings is confounded by the presence of nuclease-
inhibiting surfactant, distinct nanostructure designs,
and an alternative in vivo model system, yet the ob-
serveddiﬀerencessuggestthatDNA-basednanomater-
ials may be sensitive to their environment in a design-
dependent manner. A folate-targeted, DNA-based
nanoparticlewasalsorecentlytestedin a murinetumor
model,
33 displaying an elimination half-life (24.2 min)
and kidney uptake similar to our non-encapsulated
DNO, suggesting it may have suﬀered from a compar-
able, rapid degradation proﬁle after injection.
Finally, we proﬁled biodistribution by imaging or-
gans harvested 120 min postinjection (Figure 3d,e). No
signiﬁcant diﬀerences were observed between the
distribution proﬁles of oligonucleotide and N-DNO on
an organ-by-organ basis, and both displayed signiﬁ-
cant renal excretion with signal in urine of 86.3 ( 3.6
and88.5(2.9%(%oftotal,photons/g),respectively.In
contrast, E-DNO urine accumulation reached only
11.0 ( 4.4% of AlexaFluor750 signal at this time point,
while maintaining 85.0 ( 4.4% in blood. Dual labeling
of the E-DNO membrane (rhodamine) and DNA nano-
structure (AlexaFluor750) allowed us to compare
biodistribution of both components through multi-
plex imaging (Supporting Information Figure 9).
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No signiﬁcant diﬀerences were observed between the
two components, suggesting that they remained as-
sociated throughout imaging.
As a last comparison, we examined the biodistribu-
tion of 50 nm liposomes of the same formulation,
hydrodynamic diameter, and concentration as E-DNO
(Extended Data Figure 9). No signiﬁcant diﬀerences in
rhodamine ﬂuorescence were observed between the
major organs. Yet surprisingly, the 50 nm liposomes
cleared more rapidly than E-DNO, with twice as much
signal (38.0 ( 3.2% vs 20.1 ( 4.3%, respectively)
measured in urine. This was contrasted with 58.0 (
2.5% and 76.2 ( 3.3% signal remaining in blood of
liposome and E-DNO injected animals. Although it
requires more in-depth follow-up studies, it would be
interesting if DNO acts as a stabilizing endoskeleton
and reduces clearance of liposomes.
CONCLUSIONS
This virus-inspired E-DNO displays favorable in vitro
and in vivo properties, in stark contrast to non-
enveloped DNO which activates a potent immune
response and displays rapid degradation after injec-
tion. Using this design strategy as a starting point,
many diﬀerent biomedical applications can be con-
ceived through integration of additional functions.
Because our E-DNO incorporates a contrast agent
and has appropriate dimensions and pharmacokinetic
properties, it could easily be adapted for tumor
detection.
5Additionof ligands tothe outer membrane
leaﬂet would add speciﬁcity for target molecules or
cells, and such ligands could potentially be spatially
organized by the DNA “capsid shell” using trans-
membrane linkers. Many diﬀerent triggers could be
implementedtodriveaninternalmolecularcascadeor
a mechanical reconﬁguration of the nanostructure
frame(e.g., photon-fuelled,
34thermally
35orchemically
induced
36 conformational switch, pH-sensitive lipids
37),
which could be used for contrast agent unmasking,
drug release, or more sophisticated behaviors that
have been diﬃcult to achieve using conventional
nanomaterials or multicomponent nanodevices.
9 11
A more distant but highly exciting prospect is the devel-
opment of autonomous devices having functions ap-
proaching that of virus particles (e.g., cell entry via
attachment and fusion) or primitive immune cells (e.g.,
input-based therapeutic response), and which could pro-
vide signiﬁcant advances in diagnostics and therapeutics.
METHODS
Reagents. Lipids DOPC and DOPS, and PEG-PE, cholesterol
and rhodamine-PE, the mini-extruder, extrusion membranes,
and accessories were purchased from Avanti Polar Lipids.
Endotoxin test cartridges (0.05 5.0 EU/mL) were purchased
from Charles River. Accugene 10  TBE buffer, PCR tubes,
and 96-well PCR plates (Axygen) were purchased from VWR.
SYBR Safe and PicoGreen stains were purchased from Life
Figure 3. In vivo optical imaging for analysis of pharmacokinetics and biodistribution. Mice were injected with Alexa-
Fluor750-labeled oligonucleotide (orange), N-DNO (blue), or E-DNO dual-labeled with rh-DOPE (green) and imaged for
120minpostinjection.(a)Fluorescenceimagesofmiceat120minpostinjection.E-DNOisseenthroughoutthebody,whereas
theothertwoagentshaveaccumulatedinthebladder(calibrationbar=500 20000afu).(b)Meanﬂuorescence(measuredin
aregion-of-interesttracedaroundtheheadandtorso)vstime,relativetothesignalatt=8min(I/Io).(c)Eliminationhalf-lives
estimated from the kinetic analysis. (d) Fluorescence images of organs harvested 120 min postinjection, shown overlaid
with photographic images (i) blood, (ii) urine, (iii) lung, (iv) heart, (v) liver, (vi) kidneys, (vii) spleen, calibration bar =
1500 25000afu).(e)OrgandistributionofAlexaFluor750ﬂuorescence(%oftotal,afu/gaftercorrectingforcalculatedblood
volumes of organs). (*a,b p < 0.05, ANOVA þ Tukey's test, dashed lines and error bars indicate SEM).
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Technologies Corporation. Agarose and cell lysis buffer were
purchased from Lonza. Glycerol, Tris base, EDTA, Triton X-114,
octylβ-D-glucopyranoside(OG),Tween20,magnesiumchloride,
magnesium sulfate, sodium chloride, and paraformaldehyde
were purchased from Sigma-Aldrich. RPMI, PBS, FBS, and peni-
cillin-streptomycin were purchased from Gibco. Carbon For-
mvar grids and uranyl formate were purchased from Electron
Microscopy Sciences. The 96- and 384-well fluorescence assay
plates were purchased from BD Biosciences. Amicon Ultra
filtration devices, Optiprep media, and Seton ultracentrifuga-
tion tubes were purchased from Fisher Scientific.
DNA Nanostructure Folding. The DNA nano-octahedron was
designed using caDNAno.
23 Staples strands were purchased
reverse-phase-purified from Bioneer or Life Technologies
Corporation. Fluor-coupled oligonucleotides were custom-
synthesized and purified by IDT Technologies. The p7308
scaffold strand was produced from m13 phage replication in
Escherichia coli, as described previously.
25
The scaﬀold strand was endotoxin-puriﬁed using Triton
X-114. In brief, surfactant was added to scaﬀold stock to a ﬁnal
concentration of 2% (v/v) and incubated at 4 Con an inversion
mixer for 30 min. The solution was mixed at 37 C for 5 min to
cause phase separation, then centrifuged at 37 C for 30 min at
maximum speed in a benchtop centrifuge. The upper aqueous
fraction was transferred to a new tube. This was repeated four
times to reduce endotoxin in the scaﬀold stock solution to
acceptable levels of less than 5 EU/mL, quantiﬁed using the
Endosafe-PTS system and test cartridges (Charles River). Down-
stream DNA nanostructure puriﬁcation and dilution steps re-
duced endotoxin to undetectable levels prior to in vitro tissue
culture and in vivo imaging experiments.
Folding was tested over a range of MgCl2 concentrations. A
solution of 10nM scaﬀold was mixed with a 5-fold molar excess
of each of 144 staples strands in 5 mM Tris (pH 8.0), 1 mM EDTA
(1 TE),and10 22mMMgCl2.Thesolutionwasthensubjected
toathermalannealingramponaTetrad2Peltierthermalcycler
(Bio-Rad) according to the following schedule:
80 C for 5 min
decrease to 65 C at 5 min/C
incubate at 65 C for 20 min
decrease to 25 C at 20 min/C
Theproductswereseparatedina1.5%agarosegelþ10mM
MgCl2 and SYBR Safe stain, in 0.5  TBE buﬀer þ 10 mM MgCl2,
for3hat60V.Theleadingbandswereextractedandimagedby
TEM. We opted for a 14 mM MgCl2 concentration for the
synthesis of stock DNA nanostructures.
Negative-Stain Transmission Electron Microscopy. TEM imaging
was carried out by dropping 3.5 μL of product onto a plasma-
treated carbon Formvar grid. This was incubated for 1 min,
wicked away onto filter paper, 3.5 μL of 2% uranyl formate
(in H2O, w/v) was added for 30 s, then wicked away. Imaging
was carried out on a JEOL 1400 transmission electron micro-
scope.
Purification of Synthesized Nanostructures. Solutions of folded
DNA nanostructures were concentrated and then purified by
glycerol gradient ultracentrifugation, as described elsewhere.
26
Liposome Preparation. Liposomes were prepared using stan-
dard techniques. We produced a mixture of DOPC, PEG2K-PE,
and rhodamine-PE (molar ratio 94.2, 5.0, 0.8), or DOPC, DOPS,
PEG2K-PE, and rhodamine-PE (79.2:15:5:0.8), or DOPC, choles-
terol, PEG2K-PE, and rhodamine-PE (79.2, 15.0, 5.0, 0.8) in
chloroform in a glass tube. Chloroform was evaporated using
a dry N2 line, and the film was placed under vacuum overnight.
We added a volume of encapsulation buffer (5 mM Tris-HCl,
1mMEDTA,10mMMgCl2,10mMNaCl)tothefilm.Typically,we
wouldadd300μLofbuffertoatotalof4.5μmoloflipid.Thefilm
was resuspended by shaking on a Thermomixer (Eppendorf) at
850 rpm, room temperature for 1 h. The solution was then put
through seven rounds of freezing and thawing by passing
between liquid N2 and a room temperature water bath, then
extruded with 21 passes through a Mini-Extruder (Avanti Polar
Lipids)anda0.2μmpolycarbonatemembrane.Liposomeswere
stored at 4 C, light-protected for up to 4 weeks.
The 50 nm empty vesicles prepared for in vitro and in vivo
experiments were prepared in the same manner, except with a
50nmextrusion membraneafterextrusion through the200nm
membrane.
Lipid DNA Conjugate. The lipid DNA conjugate was synthe-
sized as described elsewhere.
27
DNA Nanostructure Encapsulation. In brief, DNA nanostructures
wereencapsulatedbyfirstannealinglipid oligonucleotideand
fluor oligonucleotide conjugates to the nanostructure in a
surfactantbuffer.Theannealedproductwaspurifiedbyglycerol
gradient, then mixed with liposomes. This was then dialyzed to
remove surfactant, and the product was purified, concentrated,
dialyzed against a buffer appropriate to downstream experi-
ments, and characterized. Sample volumes listed below were
found to be scalable.
In a typical experiment, a 400 μL solution was prepared,
containing 20 200 μg/mL DNO mixed with a 5  molar excess
(relativetohandlenumber)oflipid andﬂuor oligonucleotide
conjugates in encapsulation buﬀer þ 2% OG surfactant. The
solutionwasincubatedforaminimumof2hat35ConaTetrad
2 Peltier Cycler (Bio-Rad).
The annealed product was puriﬁed from excess lipid DNA
and ﬂuor DNA conjugates via glycerol gradients containing
OGsurfactant.Glycerolgradientswerepreparedusingsolutions
of 15% glycerol þ 2% OG and 45% glycerol þ 2% OG in en-
capsulation buﬀer.
26 The annealed product was layered on top
of the gradients and centrifuged for 2.5 h at 41000 rpm (for
SW-41 rotor tubes). The gradients were then fractionated, and
appropriate fractionswerecombinedandconcentratedbackto
the starting volume (i.e., 400 μL) using an Amicon 30K device.
The concentration of the product was determined by UV
absorbance at 260 nm on a Nanodrop system with disposable
cuvettes. The volume was transferred into a 2.0 mL microcen-
trifuge tube. Liposomes were added by transferring a 0.5 
volume of prepared liposomes into the solution (i.e., 200 μL).
This was mixed on the Thermomixer at 450 rpm, room tem-
peraturefor1h.Avolumeofencapsulation buﬀerequivalentto
the current total volume (i.e., 600 μL) was added and mixed
gently. The entire solution was then transferred into an appro-
priately sized 7K MWCO Slide-a-Lyzer dialysis cassette (Thermo
Scientiﬁc). The cassette was ﬂoated in 2 L of encapsulation
buﬀer for 3 days for small samples (e.g., 120 μL) or 7 days for
large volumes (e.g., 12 mL). Buﬀer was replaced every second
day in all cases.
After dialysis, the sample was recovered from the dialysis
cassette and concentrated using an Amicon column pretreated
with encapsulation buﬀer.
Enveloped nanostructures were separated from excess
lipids by equilibrium centrifugation using iodixanol (Optiprep
reagent,Sigma-Aldrich).Wepreparedaworkingvolumeof54%
iodixanol from the stock 60% solution by mixing with 0.1 
volume of 10  encapsulation buﬀer. We then mixed the 54%
Iodixanol/Encapsulation Buﬀer solution with 1x Encapsulation
Buﬀertoprepareequalvolumesof35,28,18,and8%iodixanol/
encapsulation buﬀer. In the case of the 35% step, the encapsu-
lated DNA nanostructure sample was used in place of 1 
encapsulation buﬀer to dilute the 54% iodixanol solution. The
volumes were layered into ultracentrifuge tubes and centri-
fuged at maximum allowable speed for 16 h, 4 C. The gradient
wasfractionated,and50μLofeachfractionwastransferredinto
a 96-well ﬂuorescence plate (BD Bioscience) and imaged onthe
Typhoonsystem(GEHealthcareLifeSciences).Thefractionation
was proﬁled by quantifying ﬂuorescent signals in each fraction
using ImageJ (NIH). The images were background-subtracted,
then a circular region-of-interest (ROI) was placed over each
well, and integrated density was measured. The integrated
density values were plotted against fraction number to proﬁle
component distribution. Appropriate fractions containing
E-DNO (based on Cy5 or AlexaFluor750 signal) were concen-
trated and washed with encapsulation buﬀer using an Amicon
centrifugation ﬁlter device or, in some cases, were ﬁrst dialyzed
against a buﬀer appropriate for downstream experiments (e.g.,
phosphate-buﬀered saline, Gibco).
The encapsulated, puriﬁed products were characterized by
TEM, DLS, and ﬂuorescence, and the encapsulation yield was
determined by a PicoGreen assay (described below). DLS was
carried out on a Nano ZS (Malvern) using standard settings.
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Fluorescence analysis was carried out on a Fluorolog (Horiba)
using the following settings. For rhodamine ﬂuorescence of
vesicles, excitation was at 550 nm and emission scanned from
575 to 700 nm. For Cy5 nanostructure ﬂuorescence, excitation
was at 625 nm and emission scanned from 650 to 800 nm.
For AlexaFluor750 ﬂuorescence, excitation was at 700 nm and
emission scanned at 725 900 nm.
PicoGreen Dye Exclusion Assay. The PicoGreen stain exclusion
assay differentiates between membrane-enclosed and non-
enclosed DNA based on the stain's inability to cross a lipid
bilayer. Measurements are made in parallel in encapsulation
buffer and buffer with OG that destabilizes the membrane and
allows the stain access to total DNA content of a sample. The
assay is carried out in a 384-well black fluorescence assay plate
(Greiner).
A standard curve was ﬁrst prepared from the DNA nano-
structure stock solutions. First 200 μLo f5μg/mL was prepared
in encapsulation buﬀer, then 6  1:2 dilutions were prepared
from this. Next 100 μL of each unknown sample was prepared
by dilution with encapsulation buﬀer (typically 1:5 1:50), aim-
ing for the concentration of the diluted sample to be within the
standard curve range. Two solutions of PicoGreen stain were
prepared by diluting the stock reagent 1:200 in either encapsu-
lation buﬀer, or encapsulation buﬀer þ 2% OG. For each
standard or sample to be measured, 10 μL of both PicoGreen
solutions was pipetted into 3  wells of the 384-well plate. Ten
microliters ofthe standardsandsamples wasthen addedtothe
6  wells, and the plate was incubated 5 min and light-pro-
tected. Fluorescence of the PicoGreen stain was measured on a
SpectraMax M5 plate reader (Molecular Devices) by excitation/
emission at 480/520 nm.
For analysis, standard curves were plotted for median
ﬂuorescence values of both the OG-negative and OG-positive
buﬀers. These were used to calculate the DNA concentration of
unknownsamples inthetwobuﬀers. Theconcentrationof DNA
in the OG-containing buﬀer equals “total DNA”, whereas that in
the encapsulation buﬀer was “non-encapsulated DNA”. Encap-
sulation yield is then calculated by
(total DNA   non-encapsulated DNA)=total DNA   100%
Nuclease Protection Assay. Sensitivity to nuclease activity was
determined using DNase I (New England Biolabs). The encap-
sulation process was carried out on 0, 12, 24, and 48 outer
handle DNA nanostructure variants at a point prior to purifica-
tionbyfloat-upcentrifugation. Onehundredmicrolitersofeach
was transferred into PCR tubes (n = 3 for DNase 1-positive and
DNase1-negative ofeachvariant, 12tubesintotal).Tenunitsof
DNase I were added to 3  replicates of each variant, and an
equivalentvolumeofDNaseIbufferwasaddedto3 replicates
as negative controls. All samples were incubated for 24 h at
37 C on a Tetrad 2 Peltier thermocycler. Following this, the
PicoGreen assay was used to determine the DNA remaining
after nuclease digestion. The percent remaining was expressed
as a ratio of the calculated DNA remaining in the DNase
I-positive samples over the DNase I-negative samples for each
design.
SplenocyteActivationAssay. RPMImedia(Gibco)usedforspleno-
cyte tissue culture were adjusted to maintain the stability of
DNAnanostructures.Mg
2þwasadjustedto6mMbyadditionof
MgSO4, diluting the media with sterile ultrapure H2O to main-
tainosmolarity.Cellviabilityandcytokineresponseinthismedi-
um was validated prior to data collection. To heat-inactivate
nuclease activity present in FBS, serum was heat-treated for
2 min at 75 C in 1 mL volumes on a Thermomixer at 1000 rpm.
Heat-inactivated serum was added to RPMI at 10%. Penicillin-
streptomycin (Gibco) was added at an appropriate dilution.
Spleens were obtained from female 8 week old C57Bl/6
mice (Charles River). Two spleens were processed for each
experiment. They were transferred into 70 μm cell strainers
(BDFalcon)andweredissociatedusingasterilesyringeplunger.
The single cell suspension was washed through the cell strainer
with 25 mL of PBS (Gibco) into a Petri dish. The suspension was
transferredtoa50mLFalcontube,andPBSwasaddedtoatotal
volumeof40mL.Thiswascentrifugedat500gfor5min,andthe
supernatant was removed and discarded. PBS (40 mL) was
added, the pellet was resuspended to wash the cells and dilute
nuclease enzymes, and the sample was respun. A total of 3 
washeswereusedtoremovenucleaseactivitycarriedoverfrom
the tissue. Two milliliters of ACK lysing buﬀer (Lonza) was
added, and the cells were gently resuspended and incubated
for7min.Followingthis,20mLofPBSand20mLofRPMImedia
were added, and the suspension was centrifuged as above. The
supernatant was discarded, and 15 mL of RPMI media was
added. After sitting for several minutes to allow settling of large
cell and tissue aggregates, the upper 10 mL of suspension was
transferred to a new 15 mL Falcon tube.
Cell concentration was determined, and 1   10
6 live cells
weretransferredin450μLto4 wellsofa48-wellplateforeach
sample to be assayed. Then, 50 μg/mL solutions of Cy5-labeled
N- and Cy5-/rhodamine E-DNO were prepared (quantiﬁcation
viaPicoGreen).Asolutionof50nmvesicleswasprepared,witha
concentration equivalent to E-DNO based onrhodamine absor-
bance. Fifty microliters of the nanostructure or vesicle samples
was transferred into the wells (n = 4). These were incubated for
16 h in a CO2 incubator at 37 C. Supernatants were removed
and centrifuged for 10 min at 500g, transferred to new tubes,
and assayed for cytokine expression immediately or stored at
 80 C.
Cytokine concentrations were determined by enzyme-
linked immunosorbant assays (R&D Systems) following the
protocols exactly.
Flow Cytometry. Cell pellets from the above splenocyte ex-
periment were fixed by addition of 1.0 mL of 4% paraformalde-
hyde/PBS solution for 15 min. Cell samples were pelleted and
washed 1  with PBS, then resuspended in 500 μL of PBS. Flow
cytometrywascarriedoutonaLSRFortessa(BD)usinga640nm
laser line with 670/30 nm emission filter to determine Cy5
fluorescence in samples (10000 events/measurement, n = 4).
Gating was performed on splenocytes and “granulocytes”
(large, granular cell population) by gating upon the FSC versus
SSC dot plot. Identical gates were applied to all samples. After
gating, a negative population was defined using the histogram
obtained for media-only negative control samples. Samples
thatshowedarightwardpeakshiftweredeterminedaspositive.
Gates were applied to Cy5 histograms for splenocytes and
granulocytes.
ConfocalImaging. Confocalimagingwascarriedoutonspleno-
cytes obtained from the above assay. The splenocytes were
stained with a 20 mM Hoechst 33342 solution for 20 min, then
resuspended in PBS. Cells were transferred into glass bottom
dishes for imaging of Cy5 and Hoechst staining using standard
filter sets and methods on an SP5 xMP inverted confocal
microscope (Leica). All images were acquired with a 63  1.2
water objective, 405 diode laser (Hoechst) and white light laser
tuned to 575 nm (Alexa 568). Emission was collected with Leica
Hybrid Detectors from 415 to 550 nm for Hoechst and
585 795 nm for Alexa 568. Optical zoom was used for higher
magnification image.
In Vivo Optical Imaging. Optical imaging experiments were
carried out on an IVIS Spectrum instrument (PerkinElmer).
Athymic C57 nude mice (Charles River) were anaesthetized
under 3% isoflurane and were then injected via tail vein with
a100μLbolusofAlexaFluor750-labeled(AF750)N-DNO,AF750/
rhodamine-labeled E-DNO at 50 nM, or rhodamine-labeled
50 nm liposomes of the same formulation used for encapsula-
tion. They were immediately transferred to the imaging system,
and data collection was initiated. Animals were maintained at
2% isoflurane throughout imaging. Fluorescence images for
kineticanalysiswereacquiredbya30sexcitationat745nmand
emission at 800 nm, every 4 min for a total of 30 images over
120 min postinjection.
Following collection of kinetic data, mice were immediately
euthanized and blood was collected by cardiac puncture and
transferredintoheparincollectiontubes.Urineandorganswere
harvested and were imaged on the IVIS system for 2 s at 570/
620 nm (rhodamine) or 30 s at 745/800 nm (AF750).
Analysis was carried out in ImageJ. In all cases, images were
background-subtracted using a 50 pixel rolling ball radius.
Pharmacokinetic analysis was carried out using the Freehand
Selection tool to draw a ROI around the complete head and
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torso of the animal to just below the front legs. The integrated
density was measured in each image. The data set was normal-
ized to the value at 8 min postinjection, as this showed peak
ﬂuorescence after diﬀusion of the agents throughout the
vascular system. Organ measurements were obtained using
the Freehand Selection tool to draw ROI around their perimeter
and measuring integrated density. Fifty microliter volumes of
blood and urine were measured. “Organ distribution” was
calculated for each organ as a percent of the total measured
arbitrary ﬂuorescent units, with urine normalized to a 200 μL
estimatedbladdervolumeandbloodto2500μLestimatedtotal
blood volume. The contribution of organ ﬂuorescence from
blood volume
38 was calculated and subtracted from total
ﬂuorescence.
Statistics. Student'sttestandANOVAwithposthocDunnet's
or Tukey's tests were performed using an excel plug-in, iner-
STAT-av1.3byMarioH.Vargas(InstitutoNacionaldeEnfermeda
Respiratorias, Mexico).
AnimalUse. Allanimalstudieswereperformedinaccordance
with NIH guidelines, under approval of Harvard University's
Institutional Animal Care and Use Committee.
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